EFFECTS OF LEVOFLOXACIN COMBINED WITH AMBROXOL ON IL-6, HPT, SAA, SP-D AND CC16 IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE COMPLICATED WITH PULMONARY INFECTION
Chunlu Wang,Ling Guo,HuizHen Li,Ping Li
DOI: https://doi.org/10.19193/0393-6384_2019_3_228
2019-01-01
Acta medica mediterranea
Abstract:Objective: To investigate the effects of levofloxacin combined with ambroxol on interleukin-6 (IL-6), haptoglobin (HPT), amyloid protein (SAA), pulmonary surfactant binding protein D (SP-D) and Clark protein 16 (CC16) in patients with chronic obstructive pulmonary disease (COPD) complicated with pulmonary infection. Methods: One-hundred and six COPD patients with pulmonary infection treated in our hospital from April 2015 to November 2017 were randomly divided into study and control groups, with 53 cases in each group. The patients in both groups were given routine treatment such as oxygen inhalation, cough relief, asthma relief, bronchospasm relief and anti-infection. The control group was treated with levofloxacin alone, while the study group was given levofloxacin combined with ambroxol on the basis of the control group. The clinical efficacy, clinical pulmonary infection score (CPIS), acute physiology and chronic health status scoring system IV (APACHE IV), pulmonary function index (forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), ratio of forced expiratory volume in the first second to forced vital capacity (FEV1 IFVC) and resting heart rate), changes of serum IL-6, HPT, SAA, SP-D, CC16, arterial blood gas analysis (arterial partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2)) and occurrence of adverse reactions were observed. Results: The total effective rate of the study group after treatment was 95.34%, a result which was significantly higher than that of the control group (75.47%, P<0.05). After treatment, the scores of CPIS and APACHE IV in the two groups were significantly lower than those before treatment, and the scores of CPIS and APACHE IV in the study group were significantly lower than those in the control group (P<0.05). After treatment, the indexes of pulmonary function and resting heart rate of the two groups were significantly increased, and the changes of the indexes in the study group were significantly higher than those in the control group (P<0.05). Compared with before treatment, the levels of IL-6, HPT, SAA and SP-D in the two groups were significantly lower and the levels of CC16 were higher after treatment, while the changes of the above-mentioned indexes in the study group were significantly higher than those in the control group (P<0.05). Compared with before treatment, the level of PaO2 increased significantly, the level of PaCO2 decreased in the study group and the change in the study group was significantly higher than that in the control group; this difference was statistically significant (P<0.05). The incidence of adverse reactions in the study group was 9.43%, a result which was significantly lower than that in the control group (26.42%, P<0.05). Conclusion: Levofloxacin combined with ambroxol is effective in the treatment of COPD patients complicated with pulmonary infection. It can regulate the changes of serum IL-6, HPT, SAA, SP-D and CC16, improve the pulmonary function of patients and has high safety and wide clinical application value.